Tags

Type your tag names separated by a space and hit enter

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
Vaccine. 2011 Feb 04; 29(7):1359-63.V

Abstract

We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p=0.539) or HIV viral load (p=0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates.

Authors+Show Affiliations

Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Qc, Canada. c.tremblay@umontreal.caNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21185423

Citation

Tremblay, Cécile L., et al. "Immunogenicity and Tolerability of an Inactivated and Adjuvanted Pandemic H1N1 Influenza Vaccine, in HIV-1-infected Patients." Vaccine, vol. 29, no. 7, 2011, pp. 1359-63.
Tremblay CL, Rouleau D, Fortin C, et al. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine. 2011;29(7):1359-63.
Tremblay, C. L., Rouleau, D., Fortin, C., Toma, E., Sylla, M., Cyr, L., Cote, S., Baz, M., Sampalis, J., Trautman, L., Sékaly, R. P., & Boivin, G. (2011). Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine, 29(7), 1359-63. https://doi.org/10.1016/j.vaccine.2010.12.023
Tremblay CL, et al. Immunogenicity and Tolerability of an Inactivated and Adjuvanted Pandemic H1N1 Influenza Vaccine, in HIV-1-infected Patients. Vaccine. 2011 Feb 4;29(7):1359-63. PubMed PMID: 21185423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. AU - Tremblay,Cécile L, AU - Rouleau,Danielle, AU - Fortin,Claude, AU - Toma,Emil, AU - Sylla,Mohamed, AU - Cyr,Lise, AU - Cote,Serge, AU - Baz,Mariana, AU - Sampalis,John, AU - Trautman,Lydie, AU - Sékaly,Rafick-Pierre, AU - Boivin,Guy, Y1 - 2010/12/23/ PY - 2010/06/25/received PY - 2010/12/06/revised PY - 2010/12/09/accepted PY - 2010/12/28/entrez PY - 2010/12/28/pubmed PY - 2011/4/26/medline SP - 1359 EP - 63 JF - Vaccine JO - Vaccine VL - 29 IS - 7 N2 - We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals. Antibody titers were determined by hemagglutination inhibition assay and by microneutralization. Vaccine was well tolerated. At 21 days post vaccination, 56 (67%) patients had seroconverted. There was no correlation between baseline CD4 cell count (p=0.539) or HIV viral load (p=0.381) and immune response. Other vaccine strategies should be evaluated in this HIV population, to improve response rates. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21185423/Immunogenicity_and_tolerability_of_an_inactivated_and_adjuvanted_pandemic_H1N1_influenza_vaccine_in_HIV_1_infected_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)01761-5 DB - PRIME DP - Unbound Medicine ER -